Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05200364
Other study ID # STRO-002-GM2
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date March 22, 2022
Est. completion date January 2024

Study information

Verified date August 2022
Source Sutro Biopharma, Inc.
Contact Craig Berman, MD
Phone 650-801-6417
Email STRO-002ClinDev@sutrobio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.


Description:

This study is a Phase 1, open-label, multicenter, dose escalation study to assess preliminary efficacy for STRO-002 combined with bevacizumab in patients with advanced ovarian cancer that is refractory or has relapsed after standard available therapy. Fallopian tube and primary peritoneal cancers are treated in the same manner as epithelial ovarian cancers and are thus included in this study. The dosing regimen will include bevacizumab administered at the labeled dose of 15 mg/kg IV q 3 weeks given together with STRO-002 at increasing dose levels administered IV q 3 weeks. The RP2D of STRO-002 given with bevacizumab 15 mg/kg q 3 weeks will be determined by dose escalation. Dose expansion will enroll approximately 40 subjects with advanced relapsed ovarian cancer treated with STRO-002 plus bevacizumab at the RP2D determined in dose escalation. Subjects in the dose expansion portion of the study will be required at screening to submit both archival tumor tissue (if available and available tissue has adequate tumor) and tumor tissue from a biopsy done during screening to the central laboratory for analysis of FOLRα expression, both prior to enrollment in the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 58
Est. completion date January 2024
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years. 2. ECOG 0-1 3. Life expectancy > 3 months 4. High Grade serous epithelial ovarian cancer (EOC), fallopian tube or primary peritoneal cancer with pathology report documentation of tumor type. 5. At least one measurable target lesion per RECIST v1.1. 6. Tumor tissue for FolRa expression testing prior to enrollment. 1. For dose escalation: tissue may be from either archival tumor tissue or from a biopsy performed during screening. 2. For dose expansion part of the study, tissue from both archival tumor tissue and a biopsy performed during screening is required. 7. Adequate bone marrow function defined as: 1. Absolute neutrophil count (ANC) =1500/µL 2. Hemoglobin = 9g/dL 3. Platelet count = 100 x 10^3/µL 8. Adequate liver function defined as: 1. ALT and AST < 2.5 x ULN 2. ALP < 2.5 x ULN 3. Bilirubin < 1.5 x ULN 9. Adequate renal function defined as serum creatinine = 1.5 x ULN or creatinine clearance (CrCl) > 40 mL/min. Subjects enrolling into Dose Escalation must also meet the following inclusion criteria: 10. Relapsed and/or PD on last treatment regimen and one of the following: 1. Primary Platinum refractory and received no more than 1 prior regimen 2. Primary platinum resistant and received no more than 4 prior regimens 3. Platinum sensitive and all of the following: - received at least 2 platinum-based therapies or received 1 platinum and 1 non-platinum based therapy (if unable to receive a second platinum regimen due to toxicity) or received at least 1 platinum-based therapy (if the regimen contained a PARP inhibitor given as maintenance treatment) - received no more than 1 additional regimen after becoming platinum resistant - received no more than 4 prior regimens Subjects enrolling into Part 2, Dose Expansion must also meet the following inclusion criteria: 11. Relapsed and/or PD on last treatment regimen and one of the following: 1. Platinum resistant and received no more than 4 prior regimens 2. Platinum sensitive and - received at least 2 platinum-based therapies or received 1 platinum and 1 non-platinum based therapy (if unable to receive a second platinum regimen due to toxicity) or received at least 1 platinum-based therapy (if the regimen contained a PARP inhibitor given as maintenance treatment) - received no more than 1 additional regimen after becoming platinum resistant - received no more than 4 prior regimens Exclusion Criteria: 1. Low grade ovarian carcinoma (Grade 1). 2. Clear cell, mucinous, endometrioid, sarcomatous, and mixed histology ovarian carcinomas, endometrial leiomyosarcoma, and endometrial stromal sarcomas. 3. Prior treatment with an ADC with a tubulin inhibitor warhead. 4. Prior treatment with other FolRa targeting agents unless approved by a Sutro medical monitor or designee. 5. Subjects who are primary platinum-refractory during frontline treatment are excluded from the Expansion Cohort (Allowed in Dose Escalation if no more than 1 prior regimen). 6. Greater than 4 prior lines of treatment (> 1 prior if primary platinum refractory). 7. Any prior toxicity that required permanent discontinuation of bevacizumab or other contraindication to receive bevacizumab per institutional guidelines. 8. Previous solid organ transplantation. 9. Current signs/symptoms of bowel obstruction and/or signs/symptoms of or bowel obstruction within 3 months of initiation of study treatment. 10. Grade =2 toxicity from prior anticancer therapy with the exception of Grade 2 alopecia or Grade 2 neuropathy. 11. Uncontrolled hypertension 12. Sensory or motor neuropathy Grade > 1 at screening prior to initiation of study treatment. 13. Potentially fatal concurrent or recent malignancy. Subjects with past or current malignancy need to be discussed with the sponsor to determine eligibility. 14. Chronic or ongoing active infection requiring systemic treatment. 15. Ongoing immunosuppressive therapy, including systemic corticosteroids. Note: Physiologic replacement and use of topical or inhaled corticosteroids are allowed. Dexamethasone may be used to treat chemotherapy induced nausea per institutional guidelines. 16. Clinically significant cardiac disease. 17. History or clinical signs of meningeal or active central nervous system involvement. 18. Known severe COPD or asthma 19. Active pneumonitis within 6 months of initiating study treatment. 20. History of stroke or history of significant cerebrovascular disease (i.e., transient ischemic attack) within 6 months of initiation of study treatment. 21. History of pulmonary embolism or any Grade 3 thromboembolic event within 6 months of initiation of study treatment. 22. Known human immunodeficiency virus seropositivity. 23. Active hepatitis B or hepatitis C and positive serology (unless due to vaccination or passive immunization due to immunoglobulin therapy) with the following exceptions: 1. Subject has had HCV but received antiviral treatment and shows no detectible HCV viral DNA for 6 months prior to screening 2. Subject has had HBV but is HBV surface antigen (HBsAg) and viral DNA negative at screening 3. Subject has had HBV but received antiviral treatment and have undetectable viral DNA for 6 months prior to screening 24. Concurrent participation in another therapeutic treatment trial 25. Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease 26. Females who are pregnant or breastfeeding, and all women of childbearing potential unwilling to use adequate barrier contraception while on treatment and for 16 weeks after last dose of STRO-002/bevacizumab and 6 months after the last dose of bevacizumab.

Study Design


Intervention

Drug:
STRO-002
intravenous antibody drug conjugate
Bevacizumab
anti-VEGF agent

Locations

Country Name City State
United States Virginia Cancer Specialists Fairfax Virginia
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Tennessee Oncology Nashville Tennessee
United States Thomas Jefferson University Philadelphia Pennsylvania
United States University of Pennsylvania Philadelphia Pennsylvania
United States University of South Florida, Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Sutro Biopharma, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1 - Safety and tolerability of STRO-002/bevacizumab as a combination therapy Incidence and severity of adverse events (AEs) and clinical laboratory abnormalities observed across STRO-002/bevacizumab dose levels. Incidence of dose-limiting toxicities (DLTs) through Day 1-21 following administration of each initial STRO-002/bevacizumab dose. From baseline through end of study (approximately 24 months)
Primary Part 1 - Determine the recommended phase 2 dose (RP2D) of STRO-002/bevacizumab Frequency of DLTs across STRO-002 dose levels From baseline through end of study (approximately 24 months)
Secondary Part 1 - Characterize the pharmacokinetics (PK) of STRO-002 by measuring the maximum plasma concentration (Cmax). Measurement of maximum plasma concentration (Cmax) after the administration of STRO-002 From baseline through end of study (approximately 24 months)
Secondary Part 1 - Characterize the PK of STRO-002 by measuring the area under the plasma concentration versus time curve (AUC) Measurement of AUC From baseline through end of study (approximately 24 months)
Secondary Part 1 - Assess the formation of anti-drug antibodies (ADAs) to STRO-002 when administered with bevacizumab. Circulating ADAs formed to STRO-002 From baseline through end of study (approximately 24 months)
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2
Active, not recruiting NCT05082025 - Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Phase 2